Lifecore Biomedical, Inc.
Lifecore Biomedical, Inc.（LFCR）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
lfcr · 股价预测 · 7 位分析师（近3月）· FMP · 更新于 2026年6月8日
分析师评级与共识
基于过去 3 个月内 7 位华尔街分析师
Buy
7 位分析师
共识
评级分布
12 个月目标价
High
$6.00
Consensus
$6.00
+7.7% upside
Low
$6.00
Median: $6 · Last Close: $5.57
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
短期股价预测
算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $5.85 | ↑ 5.00% |
1-day model range: $5.81–$5.89. Peak: $5.89 (+5.00%).
长期股价预测
年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $5 | -1.9% |
| 2028 | $5 | -2.8% |
| 2029 | $5 | -3.2% |
| 2030 | $5 | -3.4% |
| 2031 | — | -3.5% |
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · LFCR · Jun 8, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-04-29 | Barrington Research | Maintains | Outperform→Outperform |
| 2026-03-27 | Barrington Research | Maintains | Outperform→Outperform |
| 2026-03-24 | Barrington Research | Maintains | Outperform→Outperform |
| 2026-03-17 | Barrington Research | Upgrade ↑ | Market Perform→Outperform |
| 2025-01-03 | Stephens & Co. | Maintains | Equal Weight→Equal Weight |
| 2024-11-22 | Craig-Hallum | Maintains | Buy→Buy |
| 2024-08-28 | Barrington Research | Downgrade ↓ | Outperform→Market Perform |
| 2023-09-01 | Barrington Research | Maintains | Outperform→Outperform |
| 2023-09-01 | Stephens & Co. | Maintains | Equal Weight→Equal Weight |
| 2023-06-02 | Barrington Research | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on Lifecore Biomedical, Inc. (LFCR) stock. Of the recent 29 rating actions, 3 were upgrades and 7 were downgrades. 7 analysts currently cover LFCR.
分析师推荐趋势
LFCR analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$75M
↓ 42.3% YoY
Revenue Next Year
$122M
↑ 62.6% YoY
EPS This Year
$-0.48
EPS Next Year
$-1.04
↑ 117.7% YoY
EPS ForecastReported vs Estimated
Analysts forecast LFCR EPS of $-0.48 for the current fiscal year, based on estimates from 2 analysts. The LFCR revenue forecast is $75M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
LFCR 股价预测由两类独立数据源支撑：来自 7 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。LFCR 的共识目标价为 $6.00（+7.7% 上行空间），分析师共识为 Buy。
LFCR 的短期预测（明日）为 $5.85（+5.00%）。 LFCR 对 2027 年的股价预测均值为 $5。 LFCR 对 2030 年的预测区间为 $5–$6。
Lifecore Biomedical, Inc. 在 NASDAQ 上市，代码 LFCR。LFCR 在 2027 年的整体展望偏积极，在覆盖分析师中约 71% 对应 Buy 共识。
常见问题
LFCR 预测 · 8 个问题根据 7 位华尔街分析师，LFCR 的 12 个月平均目标价为 $6.00，最高 $6.00、最低 $6.00。若有图表，中位目标价可在上方查看。相对当前价 $5.57，隐含约 +7.7% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.